Small molecule · developed by PTC Therapeutics
Ataluren (PTC124, Translarna) is a drug studied in colorectal cancer, endometrial cancer and Duchenne muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01247207 | Phase 3 | Duchenne Muscular Dystrophy | Terminated | PTCT |
| NCT04014530 | Phase 1/2 | Colorectal Cancer | Recruiting | PTCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CancerEndometrium CancerDuchenne Muscular Dystrophy
Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.
See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PTCT catalysts and pipeline →